Natco Pharma has appointed Amit Parekh as Executive Vice President - Finance and Accounts of the Company with effect from 2nd December 2025 and as part of the Company`s structured succession planning; subject to necessary approvals; Amit Parekh will succeed S.V.V.N. Appa Rao, Chief Financial Officer of the Company at the Board meeting to be held in the month of February 2026. Powered by Capital Market - Live News

Natco Pharma announced that ICRA has reaffirmed/ assigned the rating ICRA AA; Stable/ ICRA A1+ for various debt facilities of the company. Powered by Capital Market - Live News

Natco Pharma today announced conclusion of US FDA Inspection at its Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit. The inspection was conducted from 17 - 21 November 2025. On conclusion of the inspection, the Company received seven observations in the Form-483. The Company believes that the observations are procedural in nature. The Company is confident to address these observations comprehensively. Powered by Capital Market - Live News

Net profit of Natco Pharma declined 23.46% to Rs 518.40 crore in the quarter ended September 2025 as against Rs 677.30 crore during the previous quarter ended September 2024. Sales declined 0.59% to Rs 1363.00 crore in the quarter ended September 2025 as against Rs 1371.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1363.001371.10 -1 OPM %42.4958.66 - PBDT666.10864.00 -23 PBT613.70818.20 -25 NP518.40677.30 -23 Powered by Capital Market - Live News

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 14 November 2025, inter alia, have recommended the interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live News